Michael R. Sierks

School for Engineering of Matter, Arizona State University

Research Area

Biography

Michael R. Sierks has not added Biography.
If you are Michael R. Sierks and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 17	2015

Other Publications

Article	Year
Degradation of beta-amyloid by proteolytic antibody light chains. Biochemistry\| PubMed ID: 14640701	2003
Residues 17-20 and 30-35 of beta-amyloid play critical roles in aggregation. Journal of neuroscience research\| PubMed ID: 14705137	2004
Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry\| PubMed ID: 15005622	2004
Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity. Biochemistry\| PubMed ID: 15170333	2004
Proteolytic antibody light chains alter beta-amyloid aggregation and prevent cytotoxicity. Biochemistry\| PubMed ID: 15287727	2004
A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 15564134	2004
Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42. Neurobiology of disease\| PubMed ID: 16137568	2005
Quantification of cytokines involved in wound healing using surface plasmon resonance. Analytical chemistry\| PubMed ID: 16255604	2005
Identification and repair of positive binding antibodies containing randomly generated amber codons from synthetic phage display libraries. Biotechnology progress\| PubMed ID: 16739981	2006
Single chain Fv antibodies against the 25-35 Abeta fragment inhibit aggregation and toxicity of Abeta42. Biochemistry\| PubMed ID: 16981713	2006
Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies. Protein engineering, design & selection : PEDS\| PubMed ID: 16984950	2006
Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. FASEB journal : official publication of the Federation of American Societies for Experimental Biology\| PubMed ID: 17068112	2006
Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. Journal of molecular biology\| PubMed ID: 17391701	2007
Single-molecule selection and recovery of structure-specific antibodies using atomic force microscopy. Nanomedicine : nanotechnology, biology, and medicine\| PubMed ID: 17662669	2007
Characterization of an antibody scFv that recognizes fibrillar insulin and beta-amyloid using atomic force microscopy. Nanomedicine : nanotechnology, biology, and medicine\| PubMed ID: 18201941	2008
Anti-oligomeric single chain variable domain antibody differentially affects huntingtin and alpha-synuclein aggregates. FEBS letters\| PubMed ID: 18230361	2008
Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells. Journal of molecular biology\| PubMed ID: 18929576	2008
Characterizing antibody specificity to different protein morphologies by AFM. Langmuir : the ACS journal of surfaces and colloids\| PubMed ID: 19090748	2009
Detecting morphologically distinct oligomeric forms of alpha-synuclein. The Journal of biological chemistry\| PubMed ID: 19141614	2009
Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells. Neuroscience letters\| PubMed ID: 19394405	2009
Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity. PloS one\| PubMed ID: 19492089	2009
Cyclodextrins promote protein aggregation posing risks for therapeutic applications. Biochemical and biophysical research communications\| PubMed ID: 19540204	2009
Antifibrillizing agents catalyze the formation of unstable intermediate aggregates of beta-amyloid. Biotechnology progress\| PubMed ID: 20306540	2010
Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm. Protein engineering, design & selection : PEDS\| PubMed ID: 20378699	2010
Engineered proteolytic nanobodies reduce Abeta burden and ameliorate Abeta-induced cytotoxicity. Biochemistry\| PubMed ID: 20429609	2010
Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model. BMC neuroscience\| PubMed ID: 20433710	2010
Nanobody specific for oligomeric β-amyloid stabilizes nontoxic form. Neurobiology of aging\| PubMed ID: 21067847	2012
Inhibiting β-secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APP. Journal of molecular biology\| PubMed ID: 21073877	2011
CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. Integrative biology : quantitative biosciences from nano to macro\| PubMed ID: 22076255	2011
Bispecific tandem single chain antibody simultaneously inhibits β-secretase and promotes α-secretase processing of AβPP. Journal of Alzheimer's disease : JAD\| PubMed ID: 22156046	2012
Isolation and characterization of antibody fragments selective for specific protein morphologies from nanogram antigen samples. Biotechnology progress\| PubMed ID: 23359572	2013
Human α4β2 nicotinic acetylcholine receptor as a novel target of oligomeric α-synuclein. PloS one\| PubMed ID: 23437071	2013
A Sensitive phage-based capture ELISA for sub-femtomolar detection of protein variants directly from biological samples. Biotechnology progress\| PubMed ID: 25203940	2014
Isolation and characterization of antibody fragments selective for toxic oligomeric tau. Neurobiology of aging\| PubMed ID: 25616912	2014